BioCentury
ARTICLE | Clinical News

Celvapan regulatory update

October 12, 2009 7:00 AM UTC

The EC approved Baxter's Celvapan H1N1 pandemic influenza vaccine. The dosing schedule consists of two 7.5 µg doses given 21 days apart. Earlier this month, EMEA's CHMP issued a positive opinion to grant marketing approval for Celvapan in adults, including pregnant women, and children ages 6 months and older (see BioCentury, Oct. 5). Baxter said it has already delivered the Vero cell-based, whole virion, inactivated swine influenza A (H1N1) vaccine to several countries, including the U.K. and Ireland, for use in their national vaccination programs. ...